AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00055640
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
Trial: NCT00055640
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
Trial: NCT00000402
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01597947
Drug: ACHN-975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single dose
Trial: NCT01597947
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous single dose
Trial: NCT02509559
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
Trial: NCT01950819
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
Trial: NCT01843010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 5ml will be intravenously infused.
Trial: NCT02633176
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
Trial: NCT01993472
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02122627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01524380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day, 10 weeks
Trial: NCT01309737
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral BID, Continuous treatment for 52 Weeks
Trial: NCT01309737
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral BID, Continuous treatment for 52 Weeks
Trial: NCT01309737
Drug: Placebo/CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Trial: NCT00255710
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00961961
Drug: Lithium / Fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized Daily Dosage
Trial: NCT02502864
Drug: Standard of Care: Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
Trial: NCT02375867
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 1 mg/Kg/day
Trial: NCT00525577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, once daily
Trial: NCT02802631
Drug: Minocin (minocycline) for Injection
RxNorm normalized name: minocycline Injection [Minocin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous formulation of minocycline, a derivative of tetracycline
Trial: NCT01658514
Drug: Met DR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin delayed-release tablets
Trial: NCT01658514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01219556
Drug: Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
RxNorm normalized name: hydrochlorothiazide / olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
Trial: NCT03437447
Drug: Cisticid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
Trial: NCT02154399
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02748967
Drug: ExPEC4V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
Trial: NCT02184637
Drug: Artemether + Lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally
Trial: NCT02748967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive single dose of Placebo on Day 1.
Trial: NCT04695509
Drug: deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
Trial: NCT00914693
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
Trial: NCT04523740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
Trial: NCT02536248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 weeks
Trial: NCT00372892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline IV placebo once per week for 4 consecutive weeks
Trial: NCT02413203
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood and urine collections before and 3 hours after celecoxib administration.
Trial: NCT02413203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood and urine collections before and 3 hours after placebo administration.
Trial: NCT00570245
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation, 10 ppm, for up to 48 hours
Trial: NCT00570245
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
Trial: NCT00884832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
Trial: NCT02337725
Drug: TVP-1012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVP-1012 1mg Tablets
Trial: NCT02337725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT02043886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
Trial: NCT01642212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02531815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for PF-06741086, single dose
Trial: NCT00981526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
Trial: NCT04370379
Drug: IBI302 (the first dose level)
RxNorm normalized name: The New Parent First Aid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q4week (3 injections) followed by PRN dosing
Trial: NCT00831376
Drug: racemic salbutamol
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Trial: NCT00831376
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Trial: NCT01206907
Drug: oxymorphone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxymorphone IR liquid
Trial: NCT02229773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229773
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02229773
Drug: BIBB 1464 MS high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01931046
Drug: Ad5-SGE-REIC/Dkk3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
Trial: NCT01228747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo tablets twice daily for 28 weeks
Trial: NCT00867750
Drug: Transarterial Chemoembolisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
Trial: NCT03569267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01073007
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mgrs daily for three months.
Trial: NCT00670787
Drug: Combination pill of losartan and hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / losartan Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
Trial: NCT02293863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
Trial: NCT02342639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT04083755
Drug: Ferric Carboxymaltose Injection [Injectafer]
RxNorm normalized name: ferric carboxymaltose Injection [Injectafer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg intravenous
Trial: NCT00083161
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
Trial: NCT00805415
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
Trial: NCT00805415
Drug: EV/DNG (SH T00658L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
Trial: NCT02097680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule every two days during four months
Trial: NCT03055026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT01485744
Drug: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
Trial: NCT00002462
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01725139
Drug: GSK2126458
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
Trial: NCT01725139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be available
Trial: NCT00477633
Drug: Norethindrone/ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet per day
Trial: NCT04776850
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02684071
Drug: Intra thecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
Trial: NCT02684071
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To be administered in conjunction with methotrexate and topotecan
Trial: NCT04479553
Drug: Qizhi Tongluo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
Trial: NCT01906749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02063529
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Trial: NCT02418130
Drug: Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02418130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03539432
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
Trial: NCT00318292
Drug: bupivacaine and epinephrine
RxNorm normalized name: Bupivacaine and epinephrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
Trial: NCT00486902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
Trial: NCT01355289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03156036
Drug: Capecitabine plus temozolomide VS Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day
Trial: NCT02978222
Drug: Adjuvant (GM-CSF) Alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection 125 μg GM-CSF
Trial: NCT04727671
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage adjustment according to the ovarian response.
Trial: NCT00541983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
Trial: NCT00470496
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo laser light exposure
Trial: NCT02000609
Drug: CHF 1535 NEXThaler 800/48
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02000609
Drug: CHF 1535 NEXThaler 200/12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02000609
Drug: CHF 1535 NEXThaler PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02000609
Drug: CHF 1535 pMDI 200/12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02000609
Drug: CHF1535 pMDI 800/48
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00864240
Drug: Clobex TM (Clobetasol) 0.05% Lotion, single exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received Galderma Laboratories, L.P. formulated products
Trial: NCT01912755
Drug: 4% articaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
Trial: NCT00619957
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
Trial: NCT01508455
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04417257
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
Trial: NCT04453111
Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe
RxNorm normalized name: Hyalgan 20 MG in 2 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid 20 mg
Trial: NCT02604004
Drug: Epivir ® tablet 150-mg single dose (drug reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Trial: NCT00535340
Drug: SR58611A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290210
Drug: URC102 0.25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290210
Drug: URC102 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290210
Drug: URC102 1.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290210
Drug: URC102 2.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290210
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02249052
Drug: AA4500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
Trial: NCT02249052
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00138086
Drug: Zevalin plus BEAM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00665119
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
Trial: NCT00665119
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9 %
Trial: NCT01923181
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration as tablets.
Trial: NCT02654938
Drug: Mobilan (M-VM3)
RxNorm normalized name: M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
Trial: NCT01575613
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
Trial: NCT02654938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% infusion solution of dextrose
Trial: NCT01253603
Drug: QAW039 capsules once daily for 28 days
FDA approved: no
EMA approved: no
PMDA approved: no